We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





New Rapid Test Determines Amount of Neutralizing Antibodies Against SARS-CoV-2 Within Short Period of Time

By LabMedica International staff writers
Posted on 03 Aug 2020
Print article
Image: New Rapid Test Determines Amount of Neutralizing Antibodies Against SARS-CoV-2 Within Short Period of Time (Photo courtesy of FSVO/Renate Boss)
Image: New Rapid Test Determines Amount of Neutralizing Antibodies Against SARS-CoV-2 Within Short Period of Time (Photo courtesy of FSVO/Renate Boss)
A Swiss-German team of researchers have developed a test that determines the amount of neutralizing antibodies against SARS-CoV-2 within a short period of time.

The test was developed at the Institute of Virology and Immunology (IVI) of the University of Bern (Bern, Switzerland) and the Swiss Federal Office for Food Safety and Animal Health (Köniz, Switzerland), and evaluated by the Ruhr-University Bochum (RUB Bochum, Germany) using serum samples from COVID-19 patients.

To determine immunity to SARS-CoV-2 and the effectiveness of potential vaccines, the amount of neutralizing antibodies in the blood of recovered or vaccinated individuals must be determined. A traditional neutralization test usually takes two to three days and must be carried out with infectious coronaviruses in a laboratory complying with biosafety level 3. The new test launched by the team of Swiss-German researchers takes only 18 hours and does not have high biosafety requirements.

In order to detect antibodies against SARS-CoV-2, the researchers used another virus that does not propagate and exchanged the envelope protein of this virus for the spike protein of the novel coronavirus, which mediates virus entry and infection. As a result, the viruses can be identified by antibodies against SARS-CoV-2 that bind to the viruses which have been altered in this way and neutralize them so that they can no longer penetrate the host cells. Since the virus pseudotyped in this way cannot propagate in host cells, no elaborate biosafety precautions are necessary for the test.

In order to determine the amount of antibodies, the researchers genetically modified the virus so that green fluorescent protein and luciferase, an enzyme from fireflies, will be produced by the infected cells. The green fluorescence is an indicator of infection with the pseudotyped virus. The less green cells found, the more neutralizing antibodies are present which block the virus. In addition, a luminometer can be used to read the luminescence signal produced by the luciferase enzyme – another way of evaluating the test.

In order to check the reliability and comparability with the conventional neutralization test, the researchers applied it to blood samples from COVID-19 patients. The direct comparison showed a good correlation between the two test systems. As compared to 56 hours for the conventional test, the new test is much faster, with only 18 hours to test results.

Related Links:
University of Bern
Swiss Federal Office for Food Safety and Animal Health
Ruhr-University Bochum


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.